Johnson & Johnson JNJ
271.22
0.54
0.20%
as of 25 Sep
- Market cap
- $652.8B
- P/E
- 31.4×
Follow JNJ
S&P 500 Member
Dividend Aristocrat
Cash Flow Champion (3y)
Revenue Champion (3y)
Insider Buys (last 12m)
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Johnson & Johnson (JNJ) Return on assets
Johnson & Johnson's return on assets over the twelve months to 30 June 2026 was 10.7%, down 3.5 percentage points from fiscal 2025 (14.1%). Over the past ten years it has ranged from 0.87% (fiscal 2017) to 19.8% (fiscal 2023); the current reading is higher than 91% of that period. That is above the Drug Manufacturers General industry median of 2.76% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Annual
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 14.1% | 6.04 |
| FY2024 | 8.09% | (11.72) |
| FY2023 | 19.8% | 10.10 |
| FY2022 | 9.71% | (1.99) |
| FY2021 | 11.7% | 2.85 |
| FY2020 | 8.85% | (0.88) |
| FY2019 | 9.73% | (0.13) |
| FY2018 | 9.86% | 8.99 |
| FY2017 | 0.87% | (11.18) |
| FY2016 | 12.1% | 0.37 |
Against its own ten years
Low 0.87%
High 19.8%
Ten-year median
9.86%
Current reading's percentile
91
Return on assets against peers
| Company | Return on assets |
|---|---|
| LLY Eli Lilly and Company compare | 22.0% |
| NVS Novartis AG compare | 11.3% |
| JNJ Johnson & Johnson | 10.7% |
| AMGN Amgen Inc. compare | 9.53% |
| AZN AstraZeneca PLC compare | 9.15% |
| ABBV AbbVie Inc. compare | 4.61% |
| MRK Merck & Co., Inc. compare | 2.57% |
| PFE Pfizer Inc. compare | 2.13% |
| GILD Gilead Sciences, Inc. compare | −6.17% |
| Drug Manufacturers General industry median | 2.76% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on JNJ
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement